Tianjin Lisheng Pharmaceutical Co Ltd Capital Reinvestment Ratio
Tianjin Lisheng Pharmaceutical Co Ltd capital reinvestment ratio. Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Capital Reinvestment Ratio of 0.07x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥287.81 Million) in capital expenditures (CN¥20.11 Million). Check total reinvestment intensity of Tianjin Lisheng Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Capital reinvestment ratio of Tianjin Lisheng Pharmaceutical Co Ltd from 2007 to 2025. This chart tracks Tianjin Lisheng Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 19 annual periods. Also explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) net asset momentum to track the company's year-over-year net asset growth rate.
Tianjin Lisheng Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2007–2025)
Tianjin Lisheng Pharmaceutical Co Ltd capital reinvestment ratio by year from 2007 to 2025. For the full cash flow conversion analysis, see 002393 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥451.85 Million | CN¥37.46 Million | ▼ -86.4% |
| 2024 | 0.61x | CN¥88.26 Million | CN¥53.75 Million | ▲ +106.7% |
| 2023 | 0.29x | CN¥209.51 Million | CN¥61.72 Million | ▲ +138.6% |
| 2022 | 0.12x | CN¥331.38 Million | CN¥40.91 Million | ▼ -72.5% |
| 2021 | 0.45x | CN¥196.34 Million | CN¥88.24 Million | ▼ -65.9% |
| 2020 | 1.32x | CN¥76.37 Million | CN¥100.66 Million | ▲ +291.0% |
| 2019 | 0.34x | CN¥268.33 Million | CN¥90.46 Million | ▼ -47.5% |
| 2018 | 0.64x | CN¥162.69 Million | CN¥104.43 Million | ▲ +129.7% |
| 2017 | 0.28x | CN¥179.25 Million | CN¥50.09 Million | ▼ -64.6% |
| 2016 | 0.79x | CN¥173.60 Million | CN¥137.20 Million | ▼ -23.5% |
| 2015 | 1.03x | CN¥198.13 Million | CN¥204.60 Million | ▼ -74.3% |
| 2014 | 4.02x | CN¥72.24 Million | CN¥290.65 Million | ▲ +272.2% |
| 2013 | 1.08x | CN¥289.62 Million | CN¥313.11 Million | ▲ +20.8% |
| 2012 | 0.89x | CN¥250.72 Million | CN¥224.35 Million | ▼ -27.4% |
| 2011 | 1.23x | CN¥134.58 Million | CN¥165.94 Million | ▲ +230.1% |
| 2010 | 0.37x | CN¥186.55 Million | CN¥69.69 Million | ▲ +316.4% |
| 2009 | 0.09x | CN¥196.14 Million | CN¥17.60 Million | ▼ -82.5% |
| 2008 | 0.51x | CN¥126.59 Million | CN¥64.86 Million | ▲ +543.9% |
| 2007 | 0.08x | CN¥174.94 Million | CN¥13.92 Million | — |